Overview

Phase 2a Pilot Study of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation

Status:
Completed

Trial end date:
2020-08-30

Target enrollment:

Participant gender:

Summary

A pilot study to explore safety and efficacy of NBMI treatment in patients with Beta Thalassemia Major requiring iron chelation Investigational product: NBMI (N1,N3-bis(2-mercaptoethyl) isophthalamide), INN: Emeramide Indication: Beta Thalassemia Major

Phase:

Phase 2

Details

Lead Sponsor:

EmeraMed

Treatments:

N,N'-Bis(2-mercaptoethyl)isophthalamide